v3.3.1.900
Segments of Business and Geographic Areas (Details 6) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Jan. 03, 2016
Sep. 27, 2015
 [3]
Jun. 28, 2015
 [4]
Mar. 29, 2015
 [5]
Dec. 28, 2014
Sep. 28, 2014
 [7]
Jun. 29, 2014
 [8]
Mar. 30, 2014
 [9]
Jan. 03, 2016
Dec. 28, 2014
Dec. 29, 2013
Revenues from External Customers and Long-Lived Assets [Line Items]                      
Worldwide total [1] $ 133,411       $ 130,358       $ 133,411 $ 130,358  
Sales Revenue, Goods, Net 17,811 [2] $ 17,102 $ 17,787 $ 17,374 18,254 [6] $ 18,467 $ 19,495 $ 18,115 70,074 74,331 $ 71,312
Operating Segments [Member]                      
Revenues from External Customers and Long-Lived Assets [Line Items]                      
Sales Revenue, Goods, Net                 70,074 74,331 71,312
Corporate, Non-Segment [Member]                      
Revenues from External Customers and Long-Lived Assets [Line Items]                      
Other non long-lived assets [1] 70,113       65,178       70,113 65,178  
Corporate, Non-Segment [Member] | General Corporate [Member]                      
Revenues from External Customers and Long-Lived Assets [Line Items]                      
Long-Lived Assets [1] 1,148       1,138       1,148 1,138  
Operating Segments [Member]                      
Revenues from External Customers and Long-Lived Assets [Line Items]                      
Long-Lived Assets [1] 62,150       64,042       62,150 64,042  
Operating Segments [Member] | United States [Member]                      
Revenues from External Customers and Long-Lived Assets [Line Items]                      
Long-Lived Assets [1] 36,609       36,835       36,609 36,835  
Sales Revenue, Goods, Net                 35,687 34,782 31,910
Operating Segments [Member] | Europe [Member]                      
Revenues from External Customers and Long-Lived Assets [Line Items]                      
Long-Lived Assets [1] 20,167       21,559       20,167 21,559  
Sales Revenue, Goods, Net                 15,995 18,947 18,599
Operating Segments [Member] | Western Hemisphere, excluding U.S. [Member]                      
Revenues from External Customers and Long-Lived Assets [Line Items]                      
Long-Lived Assets [1] 2,881       3,210       2,881 3,210  
Sales Revenue, Goods, Net                 6,045 7,160 7,421
Operating Segments [Member] | Asia-Pacific, Africa [Member]                      
Revenues from External Customers and Long-Lived Assets [Line Items]                      
Long-Lived Assets [1] $ 2,493       $ 2,438       2,493 2,438  
Sales Revenue, Goods, Net                 $ 12,347 $ 13,442 $ 13,382
[1] Long-lived assets include property, plant and equipment, net for 2015, and 2014 of $15,905 and $16,126, respectively, and intangible assets and goodwill, net for 2015 and 2014 of $47,393 and $49,054, respectively.
[2] The fourth quarter of 2015 includes a restructuring charge of $415 million after-tax ($590 million before-tax), $156 million after-tax ($214 million before-tax) from impairment of in-process research and development and Synthes integration costs of $59 million after-tax ($83 million before-tax). Additionally, the fourth quarter of 2015 includes the gain on the Cordis divestiture.
[3] The third quarter of 2015 includes net litigation expense of $348 million after-tax ($409 million before-tax).
[4] The second quarter of 2015 includes net litigation expense of $23 million after-tax ($134 million before-tax).
[5] The first quarter of 2015 includes a net litigation gain of $253 million after-tax ($402 million before-tax) and $122 million after-tax ($139 million before-tax) for costs associated with the DePuy ASRTM Hip program.
[6] The fourth quarter of 2014 includes litigation expense, primarily related to product liability and patent litigation of $652 million after-tax ($692 million before-tax), Synthes integration costs of $237 million after-tax ($325 million before-tax) and $115 million after-tax ($156 million before-tax) from impairment of in-process research and development.
[7] The third quarter of 2014 includes an additional year of the Branded Prescription Drug Fee of $220 million after and before tax, litigation expense of $231 million after-tax ($285 million before-tax), Synthes integration costs of $130 million after-tax ($167 million before-tax) and $111 million after-tax ($126 million before-tax) for costs associated with the DePuy ASRTM Hip program. Additionally, the fiscal third quarter of 2014 includes a net gain of $1.1 billion after-tax ($1.9 billion before-tax) for the divestiture of the Ortho-Clinical Diagnostics business.
[8] The second quarter of 2014 includes litigation expense of $342 million after-tax ($276 million before-tax) and Synthes integration costs of $104 million after-tax ($144 million before-tax).
[9] The first quarter of 2014 includes Synthes integration costs of $84 million after-tax ($118 million before-tax) and a $398 million tax benefit associated with Conor Medsystems.